Cloudbreak Pharma Inc.

Direct answer

Cloudbreak Pharma Inc. is publicly traded on HKSE under the ticker 2592.HK.

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical...

Can you invest in Cloudbreak Pharma Inc.?

Yes. Cloudbreak Pharma Inc. is publicly traded on HKSE under the ticker 2592.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Cloudbreak Pharma Inc.

Detailed equity research is provided by MarketSnap.